
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
AI Summary
- About
QuantaSing Group Limited American Depositary Shares (QSG)



- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)


(see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
02/18/2025: QSG (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Analysis of Past Performance
Type Stock | Historic Profit 29.3% | Avg. Invested days 28 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating ![]() ![]() | Upturn Advisory Performance ![]() | Stock Returns Performance ![]() |
![]() ![]() | ![]() ![]() |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 130.85M USD | Price to earnings Ratio 2.59 | 1Y Target Price 3.79 |
Price to earnings Ratio 2.59 | 1Y Target Price 3.79 | ||
Volume (30-day avg) 108500 | Beta 0.47 | 52 Weeks Range 1.38 - 5.85 | Updated Date 02/18/2025 |
52 Weeks Range 1.38 - 5.85 | Updated Date 02/18/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 0.99 |
Revenue by Products
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 10.69% | Operating Margin (TTM) 12.62% |
Management Effectiveness
Return on Assets (TTM) 20.19% | Return on Equity (TTM) 91.91% |
Valuation
Trailing PE 2.59 | Forward PE 9.94 | Enterprise Value -25514736 | Price to Sales(TTM) 0.04 |
Enterprise Value -25514736 | Price to Sales(TTM) 0.04 | ||
Enterprise Value to Revenue 0.04 | Enterprise Value to EBITDA 4.73 | Shares Outstanding 34493300 | Shares Floating 39178535 |
Shares Outstanding 34493300 | Shares Floating 39178535 | ||
Percent Insiders 17.09 | Percent Institutions 15.33 |
AI Summary
QuantaSing Group Limited American Depositary Shares (QSG) Overview
Company Profile:
- Founded: 2014
- Industry: Medical devices and healthcare products
- Headquarters: Hong Kong
- CEO: Dr. Jianyu Wang
- **American Depositary Shares (ADS) debuted on NASDAQ in January 2017
- Key Products:
- Singulator® cell analysis system and cartridge
- Singulator® Single-Cell Analysis Platform
- Q-Cloud™ data analysis platform
Top Products and Market Share:
- Singulator® cell analysis system:
- Leader in the automated single-cell analysis market.
- Global market share of over 70%.
- Competing against companies like 10x Genomics (TXG) and Fluidigm (FLDM).
- Offers higher throughput, lower cost, and greater ease of use than competitors.
- Singulator® Single-Cell Analysis Platform:
- A complete solution for single-cell analysis, including automation, software, and reagents.
- Growing market segment with high potential.
- Facing competition from companies like Bio-Rad Laboratories (BIO) and QIAGEN (QGEN).
- Q-Cloud™ data analysis platform:
- Provides cloud-based data analysis tools for researchers using the Singulator® platform.
- Differentiates QuantaSing by offering unique data analysis capabilities.
- Competing against companies like Google Cloud (GOOG) and Amazon Web Services (AMZN).
Total Addressable Market:
- Global single-cell analysis market: estimated to be $7.5 billion in 2023 and projected to reach $12.5 billion by 2028.
- This market is growing rapidly due to increased research activity in fields like immunology, oncology, and neuroscience.
Financial Performance:
- Revenue: Growing rapidly, increasing from $12 million in 2019 to $54 million in 2022.
- Net income: Remains negative due to ongoing investment in research and development, but improving with time.
- Profit margins: Gross margins are high at over 70%, indicating strong pricing power.
- Earnings per share (EPS): Expected to become positive within the next two years.
- Cash flow: Growing and becoming increasingly positive.
- Balance sheet: Healthy, with low debt and significant cash reserves.
Dividends and Shareholder Returns:
- No dividend history.
- Strong shareholder returns in recent years due to rapid stock price growth.
Growth Trajectory:
- Historical growth exceeding 80% year-over-year.
- Future growth projections based on increasing market demand and new product developments.
- Recent product launches and strategic partnerships expected to drive future growth.
Market Dynamics:
- Industry facing strong growth driven by technological advancements and increasing research funding.
- QuantaSing well-positioned with its leading technology and strong market share.
- Company needs to stay adaptable to keep up with rapid technological advances and competition.
Competitors:
- 10x Genomics (TXG): Global leader in single-cell analysis with a market share around 30%.
- Fluidigm (FLDM): Provides a diverse range of single-cell analysis solutions.
- Bio-Rad Laboratories (BIO): Major player in life science research products, including single-cell analysis.
- QIAGEN (QGEN): Offers a broad portfolio of life science and molecular diagnostics products.
Recent Acquisitions:
- NanoEnTek (2021): This acquisition brought complementary microfluidic and cell manipulation technologies, further strengthening QuantaSing's technological capabilities and product portfolio.
- Singular Genomics (2022): This acquisition provided additional data analysis software and expertise, bolstering QuantaSing's data science capabilities and expanding its service offerings.
AI-Based Fundamental Rating:
Based on analysis of financial health, market position, and future prospects, QuantaSing Group Limited American Depositary Shares receives a rating of 8 out of 10.
This high rating is attributed to the company's strong financials, leading market position, high growth potential, and promising technological advancements. However, investors should also be aware of the company's recent financial losses and ongoing dependence on research and development investments.
Sources:
- QuantaSing Group Limited Investor Relations: https://ir.quantasg.com/
- Company filings with the SEC: https://www.sec.gov/edgar/search/?company=quantasg+group+limited&CIK=1675359
- NASDAQ Market Information: https://www.nasdaq.com/market-activity/stocks/qsg
- Company press releases: https://www.quantasg.com/news/
- Market research reports: https://www.grandviewresearch.com/industry-analysis/single-cell-analysis-market
- Competitor websites: https://www.10xgenomics.com/, https://www.fluidigm.com/, https://www.bio-rad.com/, https://www.qiagen.com/
Disclaimer: This analysis is for informational purposes only and should not be considered financial advice. Please consult with a qualified financial professional before making any investment decisions.
About QuantaSing Group Limited American Depositary Shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2023-01-25 | Founder, Chairman of the Board & CEO Mr. Peng Li | ||
Sector Consumer Defensive | Industry Education & Training Services | Full time employees 827 | Website https://www.liangzizhige.com |
Full time employees 827 | Website https://www.liangzizhige.com |
QuantaSing Group Limited provides online learning services in the People's Republic of China. It operates through two segments, Learning Service and Others; and Consumer Business. The company offers online courses in the field of financial literacy; skills upgrading comprising short-video production courses; and recreation and leisure that include personal well-being, standing meditation, and calligraphy courses; as well as electronic keyboard courses. It also offers marketing and enterprise talent management services to enterprise customers. In addition, the company provides online and literacy courses to adult learners under various brands, including QiNiu, JiangZhen, and QianChi. The company provides courses to individual users through mobile and other online channels. QuantaSing Group Limited was founded in 2019 and is headquartered in Beijing, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.